GlassScriptPhysician profile
Craig Kraffert
NPI 1053300632
$664,713.38
in general payments reported to CMS, 2019-2025
29 companies · $119K in 2025
The $119K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139K · 2020: $60K · 2021: $59K · 2022: $65K · 2023: $87K · 2024: $137K · 2025: $119K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $285K · Travel and Lodging: $28K · Food and Beverage: $19K · Consulting Fee: $11K · Education: $118 · Honoraria: $8.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $284,932.27 |
| Travel and Lodging | $27,683.74 |
| Food and Beverage | $18,500.13 |
| Consulting Fee | $11,332.50 |
| Education | $118.09 |
| Honoraria | $8.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $181,459.60 | 2019-2025 | Ebglyss, Taltz, Olumiant |
| Abbvie INC. | $128,539.73 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $115,708.80 | 2019-2024 | Tremfya |
| Ucb, INC. | $87,014.70 | 2019-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $69,639.22 | 2019-2025 | Tremfya, Remicade, Simponi Aria |
| Galderma Laboratories, L.P. | $53,092.87 | 2024-2025 | Nemluvio, Aklief |
| Arcutis Biotherapeutics, INC. | $17,538.21 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $3,854.31 | 2021-2024 | Sotyktu, Cobenfy |
| Novartis Pharmaceuticals Corporation | $1,468.26 | 2019-2025 | |
| Incyte Corporation | $1,323.31 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $1,075.99 | 2022-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $1,042.84 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $793.04 | 2021-2025 | Siliq, Cabtreo, Jublia |
| Amgen INC. | $555.36 | 2023-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $368.10 | 2023-2024 | Vtama |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $278.54 | 2020-2025 | Dupixent |
| Journey Medical Corporation | $278.10 | 2022 | |
| Regeneron Pharmaceuticals, INC. | $185.72 | 2019-2024 | Dupixent |
| Sun Pharmaceutical Industries INC. | $135.04 | 2019-2022 | |
| Genentech USA, INC. | $124.06 | 2021-2023 | Xolair |
| Glaxosmithkline, LLC. | $71.64 | 2023 | Arexvy |
| Medtronic, INC. | $65.58 | 2025 | Venaseal |
| Botanix Sb INC | $32.78 | 2025 | Sofdra |
| Pfizer INC. | $16.90 | 2023 | |
| Organon LLC | $16.41 | 2025 | Vtama |
| Allergan, INC. | $14.24 | 2020 | |
| Almirall LLC | $12.69 | 2019 | |
| Prugen, INC. Pharmaceuticals | $7.34 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Kraffert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.